Tenax Therapeutics Faces Securities Class Action Lawsuit
A law firm has filed a class action against Tenax Therapeutics over alleged investor losses tied to securities purchased between late 2023 and mid-2026.
A New York-based law firm has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, targeting alleged damages suffered by investors who purchased the company's securities during a defined period.
Bronstein Gewirtz & Grossman, LLC filed the suit on behalf of investors who acquired TENX securities between November 13, 2023, and August 7, 2026. The firm is encouraging affected shareholders to come forward ahead of the lead plaintiff deadline of December 28, 2026.
Read more OPay Begins NYSE Trading as African Fintech Hits US Market →
The lawsuit seeks to recover damages on behalf of the investor class, though the specific allegations underlying the claims were not fully detailed in the initial announcement. Securities class actions of this type typically allege that a company or its executives made materially misleading statements or omissions that artificially affected the stock price, causing financial harm to shareholders.
Investors who believe they suffered losses during the specified class period are urged to contact the law firm to understand their potential eligibility to participate in the litigation or serve as lead plaintiff. Under federal securities law, the lead plaintiff role is generally reserved for the investor or investor group with the largest financial stake in the outcome.
Continue reading at All Financial Services & Investing
